Skip to main content
Caplight Logo









23andMe

23andMe

Private
Sunnyvale, CaliforniaHealthcare & Life Scienceshttps://23andme.com/

Last Round

M&A

Jul 14, 2025

Est. Valuation

$305M

Total Funding Raised

$1.2B

Company Overview

23andMe is a healthcare technology company that offers direct-to-consumer personal genome services through DNA collection kits, providing users with insights into their genetic ancestry, traits, and health predispositions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, E-commerce, Subscription Commerce

Business Model

B2C

Customer Profile

Hardware Sales, Data as a Service, Subscription SaaS

AI Layer

Application

Keywords

dna testingancestry reportgenetic health risksdirect-to-consumer geneticsspit kitgenomic researchdrug discoverypharmacogeneticsdata breachgenetic databaseprecision medicinebiotechdata privacy settlementtherapeutic developmentconsumer health data

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

23andMe Comparables

Compare 23andMe with similar companies based on industry and business-model similarity.

23andMe comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ProPhase Labs Inc
79%
23Mofang
78%
Genoplan
77%

23andMe Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AJul 14, 2025
BankruptcyMar 23, 2025
Follow-on OfferingOct 30, 2023
Follow-on OfferingJan 18, 2022
M&AJun 17, 2021
PIPE
Feb 4, 2021

Key People

Founding team and executive leadership

Anne Wojcicki

Co-Founder and CEO

Founding Team

Julie Davidson

Team Administrator, Office of the CEO

Executive Team

Daniel Alex

Chief Financial Officer

Executive Team

Kael Reicin

Chief Financial Officer

Executive Team

23andMe Investors

Notable investors and investment history

23andMe investors
InvestorRounds
Roche Venture FundSeries C Extension, Series C
GVSeries D, Series E, Series C Extension, Series C
New Enterprise Associates (NEA)Series A, Series B, Series D, Series E, Series C Extension, Series C
GenentechSeries A
Fidelity Management & Research CompanyPIPE, M&A, Series F, Series E
MPM BioImpactSeries D, Series E, Series C Extension, Series C
Mohr Davidow VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 14, 2025

    $305M round led by TTAM Research Institute

  • Mar 23, 2025

    $35M raised in bankruptcy round.

23andMe Filings

Explore SEC and related filing metadata, where available.

23andMe filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersSunnyvale, California
Employee Range558
Year Founded2006
Last FundingJul 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?